Kyle Bass Ampyra IPR challenge is ‘harassment’, says Acorda

16-12-2015

Kyle Bass Ampyra IPR challenge is ‘harassment’, says Acorda

B Calkins / Shutterstock.com

Biotechnology company Acorda Therapeutics has urged the Patent Trial and Appeal Board (PTAB) not to institute an inter partes review (IPR) petition filed by the Coalition for Affordable Drugs, an organisation linked to hedge fund manager Kyle Bass.


Acorda; PTAB; Coalition for Affordable Drugs; Securities Exchange Commission; Ampyra; Kyle Bass; IPR

LSIPR